LIAISON^® Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study.

ABSTRACT:

Introduction

Fecal calprotectin (FC) is established as a diagnostic marker to differentiate between inflammatory bowel diseases and non-inflammatory conditions. Furthermore, it may be effective in monitoring response to treatment, and to predict relapse during maintenance therapy.

Design

This was a prospective longitudinal study carried out in Italy, France and Spain. The primary objective was to correlate the LIAISON^® Calprotectin assay measurements to quiescent ulcerative colitis (UC) or relapse as assessed by clinical data. Patients were assessed every 3 months for 12 months, and at 18 months.

Results

The last FC measured prior to relapse was the variable that predicted relapse in a statistically significant manner. With a 62.3 μg/g cut-off the area unde

SUBMITTER: Fiorino G 

PROVIDER: S-EPMC9557957 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature